MedTrace Logo

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

NCT05420324 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-06

No results posted yet for this study

Summary

This study is a multicenter, single-arm, open-label phase II study to assess the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Conditions

  • Mucosal Melanoma

Interventions

DRUG

YH003

YH003 will be administered intravenously over 30 minutes every 21-day cycle.

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.

DRUG

albumin paclitaxel

Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.

Sponsors & Collaborators

  • Eucure (Beijing) Biopharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2024-03-04
Completion
2024-03-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05420324 on ClinicalTrials.gov